Skip to main content
Erschienen in: Strahlentherapie und Onkologie 5/2013

01.05.2013 | Original article

Comparison of four target volume definitions for pancreatic cancer

Guidelines for treatment of the lymphatics and the primary tumor

verfasst von: E. Fokas, C. Eccles, N. Patel, K.-Y. Chu, S. Warren, W. Gillies McKenna, T.B. Brunner

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Target volume definitions for radiotherapy in pancreatic ductal adenocarcinoma (PDAC) vary substantially. Some groups aim to treat the primary tumor only, whereas others include elective lymph nodes (eLNs). eLNs close to the primary tumor are often included unintentionally within the treatment volume, depending on the respective treatment philosophies. We aimed to measure the percentages of anatomical coverage of eLNs by comparing four different contouring guidelines.

Patients and methods

Planning target volumes (PTVs) were contoured using planning computed tomography (CT) scans of 11 patients with PDAC based on the Oxford, RTOG (Radiation Therapy Oncology Group), Michigan, and SCALOP (Selective Chemoradiation in Advanced Localised Pancreatic Cancer trial) guidelines. Clinical target volumes (CTVs) included the peripancreatic, para-aortic, paracaval, celiac trunk, superior mesenteric, and portal vein lymph node areas. Volumetric comparisons of the coverage of all eLN regions were conducted to illustrate the differences between the four contouring strategies.

Results

The PTV sizes of the RTOG and Oxford guidelines were comparable. The SCALOP and Michigan PTV sizes were similar to each other and significantly smaller than the RTOG and Oxford PTVs. A large variability of eLN coverage was found for the various subregions according to the respective contouring strategies.

Conclusion

This is the first study to directly compare the percentage of anatomical coverage of eLNs according to four PTVs in the same patient cohort. Potential practical consequences are discussed in detail.
Literatur
1.
Zurück zum Zitat Stathis A, Moore MJ (2012) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7:163–172CrossRef Stathis A, Moore MJ (2012) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7:163–172CrossRef
2.
Zurück zum Zitat Kessel KA, Habermehl D, Bohn C et al (2012) Database supported electronic retrospective analyses in radiation oncology: establishing a workflow using the example of pancreatic cancer. Strahlenther Onkol 188:1119–1124PubMedCrossRef Kessel KA, Habermehl D, Bohn C et al (2012) Database supported electronic retrospective analyses in radiation oncology: establishing a workflow using the example of pancreatic cancer. Strahlenther Onkol 188:1119–1124PubMedCrossRef
3.
Zurück zum Zitat Tinkl D, Grabenbauer GG, Golcher H et al (2009) Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol 185:557–566PubMedCrossRef Tinkl D, Grabenbauer GG, Golcher H et al (2009) Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol 185:557–566PubMedCrossRef
4.
Zurück zum Zitat Klautke G, Brunner TB (2008) Radiotherapy in pancreatic cancer. Strahlenther Onkol 184:557–564PubMedCrossRef Klautke G, Brunner TB (2008) Radiotherapy in pancreatic cancer. Strahlenther Onkol 184:557–564PubMedCrossRef
5.
Zurück zum Zitat Iacobuzio-Donahue CA, Fu B, Yachida S et al (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27:1806–1813PubMedCrossRef Iacobuzio-Donahue CA, Fu B, Yachida S et al (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27:1806–1813PubMedCrossRef
6.
Zurück zum Zitat Asiyanbola B, Gleisner A, Herman JM et al (2009) Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg 13:752–759PubMedCrossRef Asiyanbola B, Gleisner A, Herman JM et al (2009) Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg 13:752–759PubMedCrossRef
7.
Zurück zum Zitat Loehrer PJ Sr, Feng Y, Cardenes H et al (2011) Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29:4105–4112PubMedCrossRef Loehrer PJ Sr, Feng Y, Cardenes H et al (2011) Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29:4105–4112PubMedCrossRef
8.
Zurück zum Zitat Maluta S, Schaffer M, Pioli F et al (2011) Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer: an open-label comparative cohort trial. Strahlenther Onkol 187:619–625PubMedCrossRef Maluta S, Schaffer M, Pioli F et al (2011) Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer: an open-label comparative cohort trial. Strahlenther Onkol 187:619–625PubMedCrossRef
9.
Zurück zum Zitat Eppinga W, Lagerwaard F, Verbakel W et al (2010) Volumetric modulated arc therapy for advanced pancreatic cancer. Strahlenther Onkol 186:382–387PubMedCrossRef Eppinga W, Lagerwaard F, Verbakel W et al (2010) Volumetric modulated arc therapy for advanced pancreatic cancer. Strahlenther Onkol 186:382–387PubMedCrossRef
10.
Zurück zum Zitat Murphy JD, Adusumilli S, Griffith KA et al (2007) Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68:801–808PubMedCrossRef Murphy JD, Adusumilli S, Griffith KA et al (2007) Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68:801–808PubMedCrossRef
11.
Zurück zum Zitat Ben-Josef E, Schipper M, Francis IR et al (2011) Phase I/II radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 81:127–128CrossRef Ben-Josef E, Schipper M, Francis IR et al (2011) Phase I/II radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 81:127–128CrossRef
12.
Zurück zum Zitat Brunner TB, Scott-Brown M (2010) The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol 5:64PubMedCrossRef Brunner TB, Scott-Brown M (2010) The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol 5:64PubMedCrossRef
13.
Zurück zum Zitat Ben-Josef E, Lawrence TS (2012) Radiotherapy: the importance of local control in pancreatic cancer. Nat Rev Clin Oncol 9:9–10CrossRef Ben-Josef E, Lawrence TS (2012) Radiotherapy: the importance of local control in pancreatic cancer. Nat Rev Clin Oncol 9:9–10CrossRef
14.
Zurück zum Zitat Brunner TB, Grabenbauer GG, Klein P et al (2003) Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 55:144–153PubMedCrossRef Brunner TB, Grabenbauer GG, Klein P et al (2003) Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 55:144–153PubMedCrossRef
15.
Zurück zum Zitat Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267PubMedCrossRef Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267PubMedCrossRef
16.
Zurück zum Zitat Brunner TB, Merkel S, Grabenbauer GG et al (2005) Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis. Int J Radiat Oncol Biol Phys 62:1021–1029PubMedCrossRef Brunner TB, Merkel S, Grabenbauer GG et al (2005) Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis. Int J Radiat Oncol Biol Phys 62:1021–1029PubMedCrossRef
17.
Zurück zum Zitat Brunner TB, Baum U, Grabenbauer GG et al (2006) Large topographic variability of upper abdominal lymphatics and the consequences for radiation treatment planning. Radiother Oncol 81:190–195PubMedCrossRef Brunner TB, Baum U, Grabenbauer GG et al (2006) Large topographic variability of upper abdominal lymphatics and the consequences for radiation treatment planning. Radiother Oncol 81:190–195PubMedCrossRef
18.
Zurück zum Zitat Van Laethem JL, Hammel P, Mornex F et al (2010) Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 28:4450–4456CrossRef Van Laethem JL, Hammel P, Mornex F et al (2010) Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 28:4450–4456CrossRef
19.
Zurück zum Zitat Goodman KA, Regine WF, Dawson LA et al (2012) Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. Int J Radiat Oncol Biol Phys 83:901–908PubMed Goodman KA, Regine WF, Dawson LA et al (2012) Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. Int J Radiat Oncol Biol Phys 83:901–908PubMed
20.
Zurück zum Zitat Spalding AC, Jee KW, Vineberg K et al (2007) Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys 34:521–529PubMedCrossRef Spalding AC, Jee KW, Vineberg K et al (2007) Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys 34:521–529PubMedCrossRef
21.
Zurück zum Zitat Zhao L, Chen M, Ten Haken R et al (2007) Three-dimensional conformal radiation may deliver considerable dose of incidental nodal irradiation in patients with early stage node-negative non-small cell lung cancer when the tumor is large and centrally located. Radiother Oncol 82:153–159PubMedCrossRef Zhao L, Chen M, Ten Haken R et al (2007) Three-dimensional conformal radiation may deliver considerable dose of incidental nodal irradiation in patients with early stage node-negative non-small cell lung cancer when the tumor is large and centrally located. Radiother Oncol 82:153–159PubMedCrossRef
22.
Zurück zum Zitat Sun W, Leong CN, Zhang Z, Lu JJ (2010) Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence. Radiat Oncol 5:28PubMedCrossRef Sun W, Leong CN, Zhang Z, Lu JJ (2010) Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence. Radiat Oncol 5:28PubMedCrossRef
23.
Zurück zum Zitat Nagakawa T, Kobayashi H, Ueno K et al (1994) Clinical study of lymphatic flow to the paraaortic lymph nodes in carcinoma of the head of the pancreas. Cancer 73:1155–1162PubMedCrossRef Nagakawa T, Kobayashi H, Ueno K et al (1994) Clinical study of lymphatic flow to the paraaortic lymph nodes in carcinoma of the head of the pancreas. Cancer 73:1155–1162PubMedCrossRef
24.
Zurück zum Zitat Crane CH, Wolff RA, Abbruzzese JL et al (2001) Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol 28:25–33PubMedCrossRef Crane CH, Wolff RA, Abbruzzese JL et al (2001) Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol 28:25–33PubMedCrossRef
25.
Zurück zum Zitat Niedergethmann M, Rexin M, Hildenbrand R et al (2002) Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma. Am J Surg Pathol 26:1578–1587PubMedCrossRef Niedergethmann M, Rexin M, Hildenbrand R et al (2002) Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma. Am J Surg Pathol 26:1578–1587PubMedCrossRef
Metadaten
Titel
Comparison of four target volume definitions for pancreatic cancer
Guidelines for treatment of the lymphatics and the primary tumor
verfasst von
E. Fokas
C. Eccles
N. Patel
K.-Y. Chu
S. Warren
W. Gillies McKenna
T.B. Brunner
Publikationsdatum
01.05.2013
Verlag
Springer-Verlag
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 5/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-013-0332-3

Weitere Artikel der Ausgabe 5/2013

Strahlentherapie und Onkologie 5/2013 Zur Ausgabe

Original article

What’s in a name?

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.